Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

37.31 +0.50 (+1.36%)
Streaming Delayed Price Updated: 1:16 PM EDT, Jul 7, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,038
Open 36.76
Bid (Size) 37.29 (1)
Ask (Size) 37.33 (1)
Prev. Close 36.81
Today's Range 36.49 - 37.60
52wk Range 25.04 - 43.20
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)... 
Via Benzinga
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors. 
Via Benzinga

Performance

YTD
+14.45%
+14.45%
1 Month
+9.67%
+9.67%
3 Month
-3.72%
-3.72%
6 Month
+22.53%
+22.53%
1 Year
-5.14%
-5.14%

More News

Read More
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
Expert Ratings For Ionis Pharmaceuticals
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Via FinancialNewsMedia
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
Via Benzinga
5 Cathie Wood Stocks to Buy in June
Via InvestorPlace
Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks
Via Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
Via InvestorPlace
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Via Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Via Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Via Benzinga
Why Cramer Likes Ferguson And Stanley Black & Decker
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.